Payment overview · 2025
General Payments
$53,047.93
88 reported records · 11 companies
Healthcare provider profile · identity verified
Sunil Mehra, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · MIDDLE VILLAGE, NY · NPI 1740252295
Verified facts
What the public records show
CMS Open Payments records show Sunil Mehra, MD received $53,047.93 in general payments during 2025 across 88 reported records.
AstraZeneca Pharmaceuticals LP accounted for 97.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51,514.70 | 97.1% | 70 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $492.98 | 0.9% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $192.94 | 0.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $160.78 | 0.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $145.43 | 0.3% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.00 | 0.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $125.00 | 0.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $124.98 | 0.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $96.46 | 0.2% | 1 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $35.49 | 0.1% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $34.17 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $47,998.00 | 24 |
| Food and Beverage | $4,365.13 | 44 |
| Travel and Lodging | $684.80 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $51,155.30 | 64 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $492.98 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $228.09 | 3 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $210.94 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $192.94 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $160.78 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $160.78 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $145.43 | 6 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $96.46 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $34.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
49 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 564 | 176 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 280 | 107 |
| Prednisone | Prednisone | 237 | 145 |
| Atorvastatin Calcium | Atorvastatin Calcium | 169 | 46 |
| Breo Ellipta | Fluticasone/Vilanterol | 157 | 54 |
| Montelukast Sodium | Montelukast Sodium | 156 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 145 | 46 |
| Methylprednisolone | Methylprednisolone | 136 | 108 |
| Incruse Ellipta | Umeclidinium Bromide | 124 | 37 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 119 | 32 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 104 | 58 |
| Metformin Hcl | Metformin Hcl | 96 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 88 | 27 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 80 | 22 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 80 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 68 | 21 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 65 | 12 |
| Lisinopril | Lisinopril | 65 | 19 |
| Simvastatin | Simvastatin | 60 | 19 |
| Eliquis | Apixaban | 59 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 58 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | suppressed |
| Omeprazole | Omeprazole | 52 | 15 |
| Losartan Potassium | Losartan Potassium | 49 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 49 | 27 |
| Azithromycin | Azithromycin | 45 | 40 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 33 | 11 |
| Famotidine | Famotidine | 30 | suppressed |
| Gabapentin | Gabapentin | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Furosemide | Furosemide | 21 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Naproxen | Naproxen | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $53,047.93 · 88 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AVVIGO Guidance System, BREZTRI, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, FREESTYLE LIBRE 3, Kerendia, OFEV, Ohtuvayre, Ozempic, TEZSPIRE, TZIELD, YUPELRI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error